Sector ratings Perspective Therapeutics, Inc.

Stocks

Market Closed - NYSE Other stock markets 01:30:00 08/08/2026 am IST			5-day change	1st Jan Change
3.000 ^USD	+1.01%		+3.09%	+9.09%

28/07	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT
17/07	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
PERSPECTIVE THERAPEUTICS, INC.	34Cr	-	BBB	-	-
LONZA GROUP AG	4.95TCr		AAA
REVOLUTION MEDICINES, INC.	4.4TCr	-	B	-	-
BEONE MEDICINES AG	3.96TCr		-
IQVIA HOLDINGS INC.	3.93TCr		AAA
CELLTRION, INC.	3.24TCr		A
ASCENDIS PHARMA A/S	1.68TCr	-	-	-	-
MEDPACE HOLDINGS, INC.	1.65TCr		BBB
EUROFINS SCIENTIFIC SE	1.4TCr		AA
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	1.28TCr		AA
ICON PUBLIC LIMITED COMPANY	1.27TCr		AAA
ABIVAX	1.14TCr	-	BBB	-	-
BIO-TECHNE CORPORATION	1.13TCr		AA
PHARMARON BEIJING CO., LTD.	1.12TCr		AA
APOGEE THERAPEUTICS, INC.	1.01TCr	-	B	-	-
PRAXIS PRECISION MEDICINES, INC.	1.01TCr	-	B	-	-
PROTAGONIST THERAPEUTICS, INC.	943.9Cr		BB		-
IONIS PHARMACEUTICALS, INC.	939.94Cr	-	A	-	-
TEMPUS AI, INC.	939.16Cr		A		-
KYMERA THERAPEUTICS, INC.	894.04Cr	-	BBB	-	-
Average	1.85TCr		A
Weighted average by Cap.			A